Does Cigna Cover Testosterone Cypionate?

How Cigna Classifies Testosterone Cypionate on Its Formulary

Cigna places generic testosterone cypionate on Tier 2 or Tier 3 of its commercial formulary, depending on the specific plan. Tier 2 typically means a mid-range copay (often $30 to $60 per fill), while Tier 3 can push that to $70 or more before the deductible is met. Brand-name products such as Depo-Testosterone carry a higher tier assignment under most plan designs.

The drug's FDA-approved indication is hypogonadism in males who have primary or secondary hypogonadal conditions confirmed by clinical features and laboratory tests [1]. Cigna's medical necessity policies generally mirror this FDA label. A prescription written for off-label indications, including weight management or athletic performance, will almost certainly be denied at the PA stage.

Testosterone cypionate 200 mg/mL in a 10 mL multi-dose vial lists at approximately $100 per month at retail, but generic cash-pay pricing at compounding-friendly or discount pharmacies averages around $60 per month [2]. GoodRx and similar programs can bring single-vial pricing below $40 at certain chains.

Serum testosterone reference ranges vary by assay and laboratory [3]. The Endocrine Society's 2018 clinical practice guideline defines the lower limit of the normal male range at 264 ng/dL by LC-MS/MS methodology and recommends confirming low values on at least two separate morning draws before initiating therapy [4]. Cigna's PA criteria typically ask for exactly that documentation.

Prior Authorization Criteria for Testosterone Cypionate Through Cigna

Cigna requires prior authorization for testosterone cypionate on virtually all commercial plans. The authorization process is rated moderate in difficulty because the clinical bar is objective: you need lab results, not just a physician's clinical impression.

The standard documentation package includes:

• Two morning (7 a.m. to 10 a.m.) serum total testosterone values below the plan's threshold (commonly <300 ng/dL on the same validated assay)
• A diagnosis code from E29.1 (testicular hypofunction) or E23.0 (hypopituitarism), confirmed in the medical record
• Documentation of signs or symptoms consistent with hypogonadism (decreased libido, fatigue, reduced muscle mass, or others per the Endocrine Society guideline [4])
• Confirmation that fertility preservation has been discussed if the patient is of reproductive age, because testosterone therapy suppresses spermatogenesis [5]
• Absence of contraindications including prostate cancer, breast cancer, hematocrit above 50%, or untreated severe obstructive sleep apnea [4]

The prescribing physician or their staff submits this packet via Cigna's eviCore portal (eviCore manages specialty PA for many Cigna plans) or directly through Cigna's provider portal. Processing time for standard PA is typically 3 to 5 business days; urgent PA can be completed within 24 to 72 hours when clinical urgency is documented.

The T-Trials, published in the New England Journal of Medicine in 2016 (N=788 men aged 65 and older with confirmed hypogonadism), showed that testosterone treatment significantly improved sexual function, physical performance scores, and bone mineral density compared to placebo [6]. Cigna's own coverage rationale cites trial evidence of this quality when defining what constitutes a medically necessary indication. Prescribers who reference such data in their PA letter tend to see faster approvals.

The table below outlines the typical PA submission checklist that HealthRX clinicians use when submitting testosterone cypionate PAs for Cigna members. This framework is based on patterns observed across hundreds of submissions and is not published elsewhere.

HealthRX Cigna PA Submission Framework for Testosterone Cypionate

1. Morning testosterone x2 (same lab, LC-MS/MS preferred, drawn at least one week apart)
2. LH and FSH to classify primary vs. secondary hypogonadism [7]
3. Symptom documentation using a validated instrument such as the ADAM questionnaire or AMS scale
4. PSA and hematocrit baseline per Endocrine Society guidelines [4]
5. A brief physician letter linking symptoms, labs, and the FDA-approved indication
6. ICD-10 code on the PA form matching the code on the prescription

Missing even one of these items is the single most common reason for a Cigna PA delay, based on HealthRX clinical team experience.

What Step Therapy Requirements Exist for Testosterone Cypionate on Cigna?

Step therapy requirements for testosterone cypionate are not universal across Cigna plans, but certain plan designs do require a documented trial of an alternative testosterone delivery method first.

Some Cigna commercial plans, particularly employer-sponsored self-funded plans with aggressive formulary management, require that a patient first try testosterone gel (such as AndroGel 1.62%, FDA-approved [8]) or testosterone patches before authorizing injectable cypionate. The clinical rationale Cigna cites is cost: topical gels are often Tier 2 at a lower copay than injectables for patients who self-administer.

There are two legitimate clinical arguments a prescriber can make to bypass step therapy:

• Skin transfer risk. The FDA issued a black-box warning on testosterone topical products regarding secondary exposure in children and women through skin contact [8]. If the patient lives with young children or a pregnant partner, bypassing gels is medically justified.
• Adherence and pharmacokinetics. Daily gel application produces variable serum levels due to inter-patient differences in skin absorption [9]. Cypionate given as a biweekly 100 to 200 mg intramuscular or subcutaneous injection provides more predictable pharmacokinetics in patients who have demonstrated poor adherence to daily dosing.

Documenting either argument explicitly in the PA letter typically allows the prescriber to skip the step-therapy requirement with Cigna. Step therapy exceptions are a recognized right under the Consolidated Appropriations Act and most state insurance laws.

Does Cigna Cover Testosterone Cypionate for Weight Loss?

No. Cigna does not cover testosterone cypionate prescribed primarily for weight loss, body composition improvement, or athletic performance. These are off-label indications not recognized in the FDA product label [1].

Weight management under Cigna's pharmacy benefit is addressed through FDA-approved anti-obesity medications. Semaglutide 2.4 mg (Wegovy) in the STEP-1 trial (N=1,961) produced a mean body weight reduction of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001) [10]. Cigna's coverage of GLP-1 receptor agonists for obesity follows different PA criteria entirely.

Testosterone does have secondary effects on lean body mass and adipose tissue in men with confirmed hypogonadism. A 2013 meta-analysis of 11 randomized controlled trials (N=535) in the Journal of Clinical Endocrinology and Metabolism found that testosterone therapy reduced fat mass by a mean of 1.6 kg and increased lean mass by 1.6 kg in hypogonadal men [11]. However, that effect is incidental to the approved indication. A PA submitted with "weight loss" as the primary diagnosis will be denied. The primary ICD-10 code must reflect the hypogonadal condition.

Cigna Formulary Exceptions and Non-Formulary Coverage

If your plan's formulary does not list testosterone cypionate, or if Cigna has placed a non-preferred brand on a tier you cannot afford, a formulary exception request is an option distinct from a standard PA.

A formulary exception asks Cigna to cover a non-formulary drug or to cover a drug at a lower tier than assigned. The prescriber must submit a statement of medical necessity explaining why the formulary alternative (for example, a different testosterone product) is clinically inappropriate for the specific patient [12].

The FDA's guidance on drug labeling clarifies that testosterone cypionate and testosterone enanthate are not therapeutically interchangeable in all patients due to differences in ester half-life and injection frequency [1]. Testosterone cypionate has an approximate half-life of 8 days versus 4.5 days for testosterone propionate, meaning injection frequency and peak-to-trough variation differ clinically. This pharmacokinetic distinction can be cited when requesting a formulary exception for cypionate specifically.

Compounded Testosterone Cypionate and Cigna

Compounded testosterone cypionate, whether from a 503A or 503B pharmacy, is almost universally excluded from Cigna's standard drug benefit. Cigna's coverage policy states that compounded drugs are not covered when an FDA-approved equivalent is commercially available, which is the case for testosterone cypionate [13].

There are narrow exceptions. Patients with documented allergies to the excipients in commercially manufactured testosterone cypionate (cottonseed oil, benzyl benzoate, benzyl alcohol) may qualify for compounded coverage with a formulary exception and allergy documentation. The FDA's reference on inactive ingredient allergies provides supporting documentation for such a request [14].

The cash price for compounded testosterone cypionate at a 503A compounding pharmacy runs $40 to $80 per month depending on concentration and volume. Manufacturer savings cards do not apply to compounded products.

How to Appeal a Cigna Denial of Testosterone Cypionate

A Cigna denial of testosterone cypionate PA does not end your options. Cigna's appeal process has two internal levels followed by an external Independent Review Organization (IRO).

Level 1 Internal Appeal. File within 180 days of the denial notice. Submit a written appeal letter from the prescribing physician, updated lab results if available, and any peer-reviewed literature supporting the indication. The T-Trials data [6] and the Endocrine Society guideline [4] are appropriate citations. Cigna must respond within 30 days for standard appeals, or 72 hours for urgent appeals affecting ongoing treatment.

Level 2 Internal Appeal. If Level 1 is denied, you may escalate to a second internal review by a different Cigna medical director. The same timeline applies. This level is less commonly used but is required before accessing external review in most states.

External IRO Review. After exhausting internal appeals, you may request an independent external review. The IRO is selected by the state insurance commissioner (or by the federal process under ERISA for self-funded plans) and is not affiliated with Cigna. IRO decisions are binding on the insurer in most states. Studies of external review outcomes show that approximately 39% to 50% of external reviews result in a reversal of the insurer's decision [15].

Expedited Appeal. If a delay in treatment would seriously jeopardize health, an expedited concurrent review can run parallel to treatment. Document the clinical urgency (for example, severe symptomatic hypogonadism with cardiovascular risk factors, per the AHA/ACC cardiovascular risk framework [16]) in the request.

The American Urological Association's 2022 testosterone deficiency guideline notes: "Testosterone deficiency is a well-established, clinically significant medical condition that warrants treatment when symptoms and biochemical evidence are present" [17]. Quoting named guideline language directly in an appeal letter strengthens the medical necessity argument substantially.

Manufacturer Savings Cards and Cost-Sharing Assistance

The manufacturer of branded Depo-Testosterone (Pfizer) historically offered patient assistance, but coverage assistance programs for generic testosterone cypionate are limited because the drug is already low-cost in its generic form.

GoodRx coupons reduce the cash price of generic testosterone cypionate 200 mg/mL (10 mL vial) to $35 to $55 at major chains. Manufacturer savings cards from brand testosterone products (Aveed, Xyosted) apply only to those specific branded agents, not to generic cypionate.

Cigna's cost-sharing for testosterone cypionate under a typical commercial plan after PA approval runs $30 to $60 per 30-day supply at Tier 2, or $65 to $100 at Tier 3, before the annual deductible is satisfied. After meeting the deductible, members with coinsurance rather than flat copays may pay 20% to 30% of the negotiated price.

Insurance savings cards from manufacturers cannot legally be used as Cigna cost-sharing when the drug is on-formulary under a federal health plan such as Medicare or Medicaid. For commercial plans, check the specific card terms. The ACA does not prohibit manufacturer coupon use on commercial plans, but Cigna's own plan documents may exclude coupon value from applying to the deductible.

Monitoring Requirements That Affect Ongoing Coverage Authorization

Cigna's PA for testosterone cypionate is typically authorized for 12 months, after which a reauthorization is required. Reauthorization generally requires evidence that the patient is being monitored per evidence-based guidelines.

The Endocrine Society recommends monitoring serum testosterone levels 3 to 6 months after initiating therapy, with a target mid-normal range of 400 to 700 ng/dL on a trough draw taken just before the next injection [4]. Hematocrit should be checked at 3 and 6 months and then annually, with testosterone dose adjustment or dose interruption if hematocrit exceeds 54% [4].

PSA monitoring is required at 3 to 6 months and then per age-appropriate prostate cancer screening guidelines [18]. A PSA rise of more than 1.4 ng/mL above baseline within any 12-month period or a PSA above 4.0 ng/mL warrants urology referral before reauthorization proceeds [4].

Cigna may request office visit notes from the treating physician documenting these laboratory results at the time of reauthorization. Prescribers who use a structured monitoring note, including labs, symptom response, and any dose adjustments, tend to get reauthorizations processed faster and with fewer requests for additional information.

The Endocrine Society's guideline states: "We recommend measuring serum testosterone levels 3 to 6 months after initiating treatment and using the results to adjust the dose to achieve mid-normal range testosterone concentrations" [4]. Keeping this language in your chart note, with the actual values, is the most direct way to satisfy Cigna's reauthorization reviewers.